Compare FORM & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORM | ARWR |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.0B |
| IPO Year | 2002 | 2009 |
| Metric | FORM | ARWR |
|---|---|---|
| Price | $81.75 | $44.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $144.70 | $106.07 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $33.84 | N/A |
| Revenue Next Year | $24.66 | $109.46 |
| P/E Ratio | $46.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $47.33 | $37.06 |
| 52 Week High | $160.27 | $95.49 |
| Indicator | FORM | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 19.23 |
| Support Level | $69.88 | N/A |
| Resistance Level | $105.71 | $66.37 |
| Average True Range (ATR) | 6.85 | 2.87 |
| MACD | 0.39 | -1.00 |
| Stochastic Oscillator | 28.01 | 1.25 |
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.